首页 正文

Circulating Tumor DNA as a Prognostic Biomarker for Selecting Participants to Early Phase Clinical Trials

{{output}}
Introduction: Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critical to max... ...